“…We and others have evidence that intracellular administration of Ang II induces the expression of nuclear factor-κB ( Brasier et al, 2000 ; Ruiz-Ortega et al, 2000 ; Zhuo et al, 2006b , 2016 ; Schupp et al, 2007 ; Li and Zhuo, 2008a ), monocyte chemoattractant protein 1 (MCP-1; Zhuo, 2004 ; Li and Zhuo, 2008a ; Takahashi et al, 2008 ), TNF-α ( Takahashi et al, 2008 ), TGF-β1, and NHE3 ( Kagami et al, 1994 ; Wolf et al, 1999 ; Weigert et al, 2002 ), and induces production in the mitochondria and nucleus of the proximal tubule cells ( Gwathmey et al, 2010a , b ; Li et al, 2020 ). Furthermore, global or proximal tubule-specific overexpression of an intracellular ANG II fusion protein selectively in the proximal tubules of the kidney, Ad-sglt2-ECFP/Ang II ( Figure 1 ), or in the mitochondria of the proximal tubules, Ad-sglt2-mito-ECFP/Ang II, developed antinatriuretic responses and elevated blood pressure by altering the mitochondrial functions ( Li et al, 2011b , 2020 , 2021 ; Li and Zhuo, 2013 ). Overall, these proof of concept studies strongly support a new paradigm of a functional proximal tubule intratubular, intracellular, and mitochondrial Ang II system in the development of hypertension and renal injury.…”